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Phosphatase and tensin (PTEN) homolog gene
PTEN hamartoma tumor syndrome
Genetic mutation
was grade 1 endometrial carcinoma arising from endometrial/cervical
polyp (Fig. 1). The patient was then referred to our gynecologic oncology
practice.
The patient's past medical history was notable for both motor and
cognitive developmental delays. On physical exam, the patient was
noted to have a head circumference of 63 cm (>97th percentile),
two thyroid masses measuring 3 and 6 cm and involving both lobes
of the gland, and a right upper medial quadrant breast mass measur-
ing approximately 2 cm. Sexual development was Tanner stage IV for
both breast and pubic hair. The patient's father had a similar appear-
ance of macrocephaly, as well as developmental delay, skin nodulesgoiter and a recent non-cancerous pancreatic tumor.
Introduction
Cowden Syndrome (CS) is a rare, autosomal dominant disorder af-
fecting approximately 1 in every 200,000 people. CS involves a germline
mutation in the phosphatase and tensin (PTEN) homolog gene, which
encodes a tumor suppressor antagonizing the phosphatidylinositol
3-kinase (PI3K/AKT) and mitogen-activated protein kinase (MAPK)
pathway (Hobert and Eng, 2009). CS is associated with the development
of hamartomas, as well as an increased lifetime risk of breast (25–50%),
thyroid (10%), renal (13–34%), colorectal (16%) and endometrial carcino-
mas (13–19%); forming the prototype of the PTEN hamartoma tumor
syndrome (PHTS) (Gammon et al., 2009). Physical manifestations may
include macrocephaly, trichilemmomas and papillomatous papules.
Case report
A 15-year-old virginal female complained to her primary care physi-
cian of excessive vaginal bleeding. She reported 2–3 cycles per month
with menses lasting 5–7 days. Menarche was at 13 years of age and
had previously been normal. On examination, a cervical mass was
seen but poorly evaluated at this time due to intolerance of exam.
Papanicolaou test revealed atypical squamous cells of undetermined sig-
niﬁcance. She was examined under anesthesia, and a 3 cm polyp at theology, Suite E102, 853 Jefferson
.
-ND license.suggestive of papillomatous papules, a remote history of thyroid
The patient was referred to St. Jude Children's Research Hospital for
ongoing care. The diagnosis of CSwas suspected clinically, and compre-
hensive PTENmutational analysis identiﬁed a heterozygous truncating
mutation in the PTEN gene (c. 467 470dupGGGA). Given the patient's
young age, a conservative approachwas appropriate. Computed tomog-
raphy scan of the chest, abdomen, and pelvis was negative formetastat-
ic disease. The patient then underwent hysteroscopy with dilation and
curettage. Hysteroscopy revealed multiple polyps in the endometrium.
Curettage and evacuation of polypswith polyp forcepswere performed.
Pathology revealed endometrioid adenocarcinoma, grade 1.
The patient and familywere extensively counseled on treatment op-
tions by both pediatric oncology at St. Jude and gynecologic oncology.
Options consisted of fertility preserving therapy with hormonal agents
versus deﬁnitive therapy consisting of hysterectomy. The patient and
family elected for deﬁnitive therapy, and the patient underwent a
total abdominal hysterectomywith pelvic and paraaortic lymphadenec-
tomy. Intraoperatively, bilateral ovarian biopsieswere obtained. Pathol-
ogy showed atypical cells in the right ovary; thus, a right oopherectomy
was performed with preservation of the left ovary. Final pathology
revealed stage IA endometrial adenocarcinoma, FIGO grade 1, invasive
into the superﬁcial 1/3 of themyometrium.No lymphatic/vascular inva-
sion was identiﬁed. The right ovary demonstrated normal ovarian
parenchyma on ﬁnal pathology, with no malignancy; pelvic and
paraaortic lymph nodes were negative for malignancy, and abdominal
washings were negative for neoplastic cells. The patient's postoperative
recovery was uneventful.
Twomonths after surgery, the patient underwent near total thyroid-
ectomy and received radioactive iodine for residual thyroid ablation
Fig. 1. Endocervical polyp demonstrating the crowded branching gland component of
the polyp with cytologic atypia (400×).
19A.C. ElNaggar et al. / Gynecologic Oncology Reports 3 (2013) 18–19(32.5 mCi I-131). Biopsy of the breast mass showed focally ﬁbrotic
mammary gland tissue suggestive of, but not diagnostic of, lobular neo-
plasia. The patient has now been in remission for 3 years from both thy-
roid and endometrial cancer at the time of this submission.
Comment
PTEN tumor suppressor gene somaticmutations have been reported
in approximately 40% of endometrial adenocarcinomas and constitute
the most frequent genetic lesion (Mutter et al., 2000). Furthermore,
persons with CS have a 13 to 19% lifetime risk of endometrial cancer
(Riegert-Johnson et al., 2010). Despite these ﬁndings, the National
Comprehensive Cancer Network (NCCN) guidelines do not endorse
any endometrial cancer screening aside from patient education and
awareness of symptoms of endometrial cancer.
Conversely, cancer screening in regard to breast and thyroid ma-
lignancies is well deﬁned and recommended for CS patients begin-
ning at 18 years of age or 5 years before the family's earliest age of
cancer diagnosis (Hobert and Eng, 2009; Gammon et al., 2009).
This case illustrates the importance of recognizing both the features
of CS and the clinicalmanifestations of its associated cancers, whichmay
present during adolescence. Due to the inherent risk of endometrialcancer and the possibility of premenopausal development of endometri-
al cancer, adopting the guidelines for Lynch Syndrome should be
considered; use of annual endometrial biopsies beginning at age 30 to
35 or 5 years before the earliest family diagnosis of endometrial cancer
(Renkonen-Sinisalo et al., 2007; Auranen and Joutsiniemi, 2011). Post-
menopausal recommendations may include annual ultrasonographic
examination with biopsy of suspicious areas due to the improved sensi-
tivity of detecting uterine pathology in this population (Smith-Bindman
et al., 1998).
Another important recommendation is that of prophylactic hysterec-
tomy. In patients with germ-line mutations associated with Lynch Syn-
drome, prophylactic hysterectomy and bilateral salpingo-oophorectomy
prevented 100% of new uterine or ovarianmalignancies when compared
with controls who did not undergo prophylactic surgery (Schmeler et al.,
2006).
With our experience, there seems to be no minimal age for
performing endometrial biopsy if abnormal bleeding is found in
patients suspected of CS. Collaboration with a genetic specialist is
essential in diagnosing and managing CS. Awareness of the clinical
phenotype (macrocephaly, trichilemmomas, and/or papillomatous
papules) combined with a thorough physical examination are impor-
tant in alerting physicians to a possible diagnosis of CS. For patients
conﬁrmed to have CS, counseling about the risks of breast, thyroid,
and endometrial malignancy is important, as is routine screening for
breast and thyroid cancer.
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